Keyphrases
Ranibizumab
100%
Neovascular Age-related Macular Degeneration (nAMD)
100%
Inactivity
100%
Visual Acuity
60%
Best-corrected Visual Acuity
40%
Active Treatment
40%
Retrospective Chart Review
20%
Apparent Disease
20%
Treatment Discontinuation
20%
Loading Dose
20%
Financial Disclosure
20%
Standardized Mortality Ratio
20%
Treatment Response
20%
Acuity
20%
Fellow Eye
20%
Complication Rate
20%
Intravitreal Injection
20%
Patient Data
20%
Clinical Examination
20%
Dosing Regimen
20%
Close Follow-up
20%
Patient-initiated
20%
Community Hospital
20%
Visual Outcome
20%
Endophthalmitis
20%
Mortality Rate
20%
Number of Injections
20%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
100%
Ranibizumab
100%
Wet Macular Degeneration
100%
Mortality Rate
50%
Vasculotropin
25%
Endophthalmitis
25%
Intravitreal Administration
25%